Florentia Dimitriou
Overview
Explore the profile of Florentia Dimitriou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esmaeli B, Ogden T, Nichols M, Lu T, Debnam J, Dimitriou F, et al.
Melanoma Res
. 2024 Dec;
35(2):130-144.
PMID: 39656585
Our primary objective was to estimate the overall response rate to immune checkpoint inhibitors (ICIs) in patients with locally advanced, multiply recurrent, or metastatic conjunctival melanoma treated with ICIs. A...
2.
Dimitriou F, Orloff M, Koch Hein E, Cheng P, Hughes I, Simeone E, et al.
Eur J Cancer
. 2024 Dec;
214:115161.
PMID: 39647344
Background: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to...
3.
Mangana J, Lamos C, Ozdemir B, Laubli H, Morgan L, Maul L, et al.
Skin Health Dis
. 2024 Dec;
4(6):e442.
PMID: 39624750
There is a need to understand the journey of patients with melanoma, including any associated gender differences, to identify aspects in the patient journey that could be improved. We used...
4.
Woodford R, McKeown J, Hoeijmakers L, Mangana J, Dimitriou F, Allayous C, et al.
Eur J Cancer
. 2024 Oct;
212:115055.
PMID: 39366209
Introduction: Approximately 50 % of resected stage II-IV melanoma patients develop recurrent disease by 5 years despite adjuvant anti-PD-1 therapy. Data to define best management of recurrences is lacking. Methods:...
5.
Maurer A, Clerici G, Schaab J, Cheng P, Mihic-Probst D, Mader C, et al.
Clin Exp Med
. 2024 Oct;
24(1):234.
PMID: 39352553
Metastatic uveal melanoma (mUM) is associated with poor prognosis. Ipilimumab/nivolumab has shown antitumor efficacy in phase II studies. Tebentafusp resulted in longer overall survival (OS) compared to investigator`s choice in...
6.
Dimitriou F, Cheng P, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerdinger V, et al.
Nat Cancer
. 2024 Aug;
5(9):1390-1408.
PMID: 39210005
Immune checkpoint inhibitors are standard-of-care for the treatment of advanced melanoma, but their use is limited by immune-related adverse events. Proteomic analyses and multiplex cytokine and chemokine assays from serum...
7.
Vasilevska J, Cheng P, Lehmann J, Ramelyte E, Gomez J, Dimitriou F, et al.
Cell Rep Med
. 2024 Jun;
5(7):101611.
PMID: 38942020
Resistance to targeted therapy remains a major clinical challenge in melanoma. To uncover resistance mechanisms, we perform single-cell RNA sequencing on fine-needle aspirates from resistant and responding tumors of patients...
8.
Taylor M, Nelson K, Dimitriou F
Hematol Oncol Clin North Am
. 2024 May;
38(4):851-868.
PMID: 38782646
Skin cancers, including melanoma and keratinocyte carcinomas, are responsible for increasing health care burden internationally. Risk stratification and early detection are paramount for prevention and less risky treatment to overall...
9.
Albrecht L, Dimitriou F, Grover P, Hassel J, Erdmann M, Forschner A, et al.
Eur J Cancer
. 2024 Mar;
202:113976.
PMID: 38484692
Background: Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI...
10.
Taylor A, McKeown J, Dimitriou F, Jacques S, Zimmer L, Allayous C, et al.
Eur J Cancer
. 2024 Jan;
199:113561.
PMID: 38278009
Background: Anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. BRAFV600-mutated (BRAFmut) melanoma patients who recur with isolated disease following adjuvant...